Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement
- PMID: 22474106
- PMCID: PMC3522117
- DOI: 10.1001/archgenpsychiatry.2011.1603
Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement
Abstract
Context: Estimates of DSM-IV disorder prevalence are high; stringent criteria to define need for services are desired.
Objective: To present US national data on the prevalence and sociodemographic correlates of 12-month serious emotional disturbance (SED), defined by the US Substance Abuse and Mental Health Services Administration, from the National Comorbidity Survey Replication Adolescent Supplement.
Design: The National Comorbidity Survey Replication Adolescent Supplement is a national survey of DSM-IV anxiety, mood, behavior, and substance disorders among US adolescents.
Setting: Dual-frame household and school samples of US adolescents.
Participants: Total of 6483 pairs of adolescents aged 13 to 17 (interviews) and parents (questionnaires).
Main outcome measures: The DSM-IV disorders were assessed with the World Health Organization Composite International Diagnostic Interview and validated with blinded clinical interviews based on the Schedule for Affective Disorders and Schizophrenia for School-Age Children. Serious emotional disturbance was operationalized as a DSM-IV/Composite International Diagnostic Interview disorder with a score of 50 or less on the Children's Global Assessment Scale (ie, moderate impairment in most areas of functioning or severe impairment in at least 1 area). Concordance of Composite International Diagnostic Interview SED diagnoses with blinded Schedule for Affective Disorders and Schizophrenia for School-Age Children diagnoses was good.
Results: The estimated prevalence of SED was 8.0%. Most SEDs were due to behavior (54.5%) or mood (31.4%) disorders. Although respondents with 3 or more disorders made up only 29.0% of those with 12-month DSM-IV/Composite International Diagnostic Interview disorders, they constituted 63.5% of SEDs. Predictive effects of high comorbidity were significantly greater than the product of their disorder-specific odds ratios and consistent across disorder types. Associations of sociodemographic variables with SED were generally nonsignificant after controlling for disorder type and number.
Conclusions: The high estimated 12-month prevalence of DSM-IV disorders among US adolescents is largely due to mild cases. The significant between-disorder differences in risk of SED and the significant effect of high comorbidity have important public health implications for targeting interventions.
Figures
References
-
- Costello EJ, Egger H, Angold A. 10-year research update review: the epidemiology of child and adolescent psychiatric disorders, I: methods and public health burden. J Am Acad Child Adolesc Psychiatry. 2005;44(10):972–986. - PubMed
-
- Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He J, Koretz D, McLaughlin KA, Sampson NA, Merikangas KR. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the US National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. doi: 10.1001/archgenpsychiatry .2011.160. [published online ahead of print December 5, 2011] - DOI - PMC - PubMed
-
- Regier DA, Kaelber CT, Rae DS, Farmer ME, Knauper B, Kessler RC, Norquist GS. Limitations of diagnostic criteria and assessment instruments for mental disorders: implications for research and policy. Arch Gen Psychiatry. 1998;55 (2):109–115. - PubMed
-
- Spitzer RL. Diagnosis and need for treatment are not the same. Arch Gen Psychiatry. 1998;55(2):120. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 DA016558/DA/NIDA NIH HHS/United States
- R01 MH066627/MH/NIMH NIH HHS/United States
- U01-MH60220/MH/NIMH NIH HHS/United States
- R01-MH070884/MH/NIMH NIH HHS/United States
- R03 TW006481/TW/FIC NIH HHS/United States
- R01 MH069864/MH/NIMH NIH HHS/United States
- R01-DA016558/DA/NIDA NIH HHS/United States
- R01-MH069864/MH/NIMH NIH HHS/United States
- U01MH060220-09S1/MH/NIMH NIH HHS/United States
- R13-MH066849/MH/NIMH NIH HHS/United States
- R01 MH070884/MH/NIMH NIH HHS/United States
- K01 MH092526/MH/NIMH NIH HHS/United States
- R01 MH077883/MH/NIMH NIH HHS/United States
- R13 MH066849/MH/NIMH NIH HHS/United States
- K05 DA015799/DA/NIDA NIH HHS/United States
- R03-TW006481/TW/FIC NIH HHS/United States
- U01 MH060220/MH/NIMH NIH HHS/United States
- R01-MH66627/MH/NIMH NIH HHS/United States
- R01-MH077883/MH/NIMH NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States